izpis_h1_title_alt

Randomized, double-blinded, controlled trial of the effects of coenzyme Q10 supplementation on plasma coenzyme Q10 concentration in dogs with myxomatous mitral valve disease
ID Druzhaeva, Natalia (Avtor), ID Domanjko-Petrič, Aleksandra (Avtor), ID Tavčar-Kalcher, Gabrijela (Avtor), ID Babič, Janja (Avtor), ID Nemec Svete, Alenka (Avtor)

.docxDOCX - Predstavitvena datoteka, prenos (70,87 KB)
MD5: 1B990652128DEC72D723FAF05497B941
URLURL - Izvorni URL, za dostop obiščite https://avmajournals.avma.org/doi/10.2460/ajvr.82.4.280 Povezava se odpre v novem oknu
Opis: Dostopno z geslom

Izvleček
OBJECTIVE To determine the dose of coenzyme Q10 (CoQ10) needed to achieve at least a 3-fold increase in plasma CoQ10 concentration in dogs with myxomatous mitral valve disease (MMVD) and congestive heart failure (CHF). ANIMALS 18 dogs with CHF due to MMVD and 12 healthy dogs. PROCEDURES In a randomized, double-blinded, controlled trial, dogs with MMVD were given 50 or 100 mg of water-soluble CoQ10 (ubiquinone; total daily dose, 100 mg [n = 5] or 200 mg [6]) or a placebo (7), PO, twice a day for 2 weeks in addition to regular cardiac treatment. Plasma CoQ10 concentration was measured in dogs with MMVD before (baseline) and at various time points after supplementation began and in healthy dogs once. Concentrations were compared among and within groups. RESULTS No significant difference in median baseline plasma CoQ10 concentration was detected between healthy dogs and dogs with MMVD. Fold increases in plasma CoQ10 concentrations ranged from 1.7 to 4.7 and 3.2 to 6.8 for in- dividual dogs in the 100-mg and 200-mg groups, respectively. The change in plasma CoQ10 concentration after supplementation began was significantly higher than in the placebo group at 4 hours and 1 and 2 weeks for dogs in the 200-mg group and at 1 and 2 weeks for dogs in the 100-mg group. CONCLUSIONS AND CLINICAL RELEVANCE A daily CoQ10 dose of 200 mg was sufficient to achieve at least a 3-fold increase in plasma CoQ10 concentration and may be used in CoQ10 supple- mentation studies involving dogs with CHF due to MMVD.

Jezik:Angleški jezik
Ključne besede:congestive heart failure, coenzyme Q10, myxomatous mitral valve disease, dogs
Vrsta gradiva:Članek v reviji
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:VF - Veterinarska fakulteta
Status publikacije:Objavljeno
Različica publikacije:Recenzirani rokopis
Datum sprejetja članka:17.08.2020
Leto izida:2021
Št. strani:Str. 280-285
Številčenje:Vol. 82, no. 4
PID:20.500.12556/RUL-132360 Povezava se odpre v novem oknu
UDK:636.09:616
ISSN pri članku:0002-9645
DOI:10.2460/ajvr.82.4.280 Povezava se odpre v novem oknu
COBISS.SI-ID:57671939 Povezava se odpre v novem oknu
Datum objave v RUL:22.10.2021
Število ogledov:803
Število prenosov:146
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:American journal of veterinary research
Skrajšan naslov:Am. j. vet. res.
Založnik:American Veterinary Medical Association.
ISSN:0002-9645
COBISS.SI-ID:5084423 Povezava se odpre v novem oknu

Licence

Licenca:CC BY-NC-ND 4.0, Creative Commons Priznanje avtorstva-Nekomercialno-Brez predelav 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by-nc-nd/4.0/deed.sl
Opis:Najbolj omejujoča licenca Creative Commons. Uporabniki lahko prenesejo in delijo delo v nekomercialne namene in ga ne smejo uporabiti za nobene druge namene.
Začetek licenciranja:15.04.2021

Projekti

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:P4-0053
Naslov:Endokrini, imunski in encimski odzivi pri zdravih in bolnih živalih

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj